Nicotine Bitartrate Dihydrate: The Preferred Nicotine Form for Pouches and NRT

Every nicotine pouch on the market faces the same core engineering problem: deliver a precise dose of nicotine from a dry format, consistently, for 12+ months of shelf life. Nicotine bitartrate dihydrate solves that problem better than any alternative. That is why it has become the default nicotine form for the fastest-growing product category in the industry.

What It Is

Nicotine bitartrate dihydrate is a salt formed by combining pharmaceutical-grade freebase nicotine with L-tartaric acid in a 1:2 molar ratio. The compound crystallizes with two water molecules (the "dihydrate" part), producing a stable white crystalline powder with the molecular formula C₁₀H₁₄N₂·2C₄H₆O₆·2H₂O and a molecular weight of approximately 498.4 g/mol (PubChem CID 57351368).

Roughly 36 of those 498.4 g/mol is water of crystallization. That single fact governs how you have to read every nicotine percentage quoted for this material, because a percentage is meaningless until you know what mass it was measured against. A figure reported as supplied includes the water you weigh out with the powder. A figure reported on a dried or anhydrous basis excludes it. Run the same salt both ways and the reported percentage moves by roughly 8%, which is more than enough to put a milligram-target dose outside its tolerance.

Nicotine content here is bounded rather than open-ended. Because the compound is a crystalline salt of defined stoichiometry, the material is released against a narrow specification: 30.0 to 35.0% nicotine, with every lot assayed against that band. The lot certificate for the material we supply reports 32.57%, and the theoretical value from the molecule itself is 32.5% (162.23 g/mol of nicotine in a 498.4 g/mol salt). That is not the same as saying the content does not vary. A five-point release range exists precisely to absorb assay variation, hydration and normal material variation. What the defined stoichiometry plus a tight release specification actually buys you is a narrow, documented range to formulate against and a batch-specific number on every certificate. Compare that to working with liquid freebase nicotine, where concentration varies with dilution and drifts over time through oxidation and evaporation, and the advantage is as much the documentation as the chemistry.

The crystalline form also makes incoming inspection straightforward. The batch record for this material identifies it by infrared absorption against the nicotine bitartrate dihydrate reference standard, and describes the material as a white or almost white powder. Both are checks you can run against a drum before you commit it to a batch.

Why It Wins on the Manufacturing Floor

Stability That Liquid Nicotine Cannot Match

Liquid freebase nicotine oxidizes. It degrades with light exposure. It discolors over time. You are fighting chemistry from the moment it leaves the supplier. Freebase nicotine at high purity starts as a nearly colorless liquid and can turn amber or brown within weeks if improperly stored. That degradation is not just cosmetic. Oxidized nicotine produces cotinine and nicotine-N-oxide, both of which affect the safety and efficacy profile of the finished product.

Nicotine bitartrate dihydrate in crystalline form resists all three degradation pathways under normal storage conditions. The salt form locks the nicotine molecule into a stable crystal lattice. Light, heat, and oxygen have a much harder time reaching the active compound. How far that protection extends under your own storage conditions is a question for data rather than for a rule of thumb, so ask the supplier for the accelerated and long-term stability results behind the grade you are buying instead of accepting a shelf-life figure on its own.

That translates directly to longer product shelf life and less waste. For a manufacturer running tight margins on a high-volume SKU, the difference in scrap rates alone justifies the switch. The mechanism behind that is straightforward. When the active ingredient does not degrade appreciably in the drum, the assay you qualified against is still the assay you dose against weeks later, so nicotine content failures caused by storage-driven degradation stop being a category of loss you have to plan around.

Dosing Precision That Satisfies Regulators

The defined nicotine-to-salt ratio of the crystalline form removes a whole class of variability that comes with liquid nicotine handling. Volumetric dosing of a viscous liquid carries pump and pipetting error, temperature-dependent density, and residue left in the line. Gravimetric dosing of a dry powder on a calibrated analytical balance carries none of those. The tolerance you can hold becomes a property of your balance and your process rather than of the material, which is exactly the kind of variable a quality system is built to control.

For pouch manufacturing, this matters at every scale. Run the dose calculation against the assayed value on the lot's own COA rather than against the nominal 30 to 35% band, and settle one question with your supplier before you divide by that value: which basis the assay is reported on. For a hydrated salt, an as-supplied figure and a figure reported on the dried or anhydrous basis are not interchangeable, and reaching for the wrong one moves your dose by several percent. Once the basis is settled, the arithmetic is a single step. A lot certificate reporting 32.57% as supplied means a 4mg pouch takes 12.28mg of powder: 4 divided by 0.3257. The math is clean, the QC is simple, and the regulatory filing writes itself. When the FDA or a European notified body asks how you control nicotine content in your finished product, pointing to a gravimetric dosing process with a crystalline salt of defined composition is about as clean an answer as you can give.

The uniformity of the powder also matters for blend homogeneity. In pouch production, the nicotine source is blended with fillers (typically microcrystalline cellulose, hydroxypropyl cellulose, or similar), pH adjusters, flavorings, and humectants. A crystalline powder with consistent particle size distribution mixes more uniformly than a liquid sprayed onto a carrier. This reduces the coefficient of variation on nicotine content between individual pouches within a batch, which is a metric regulators pay close attention to.

Safer to Handle

Liquid nicotine at production concentrations is a dermal absorption hazard. At concentrations above 10%, accidental skin contact can produce symptoms of nicotine poisoning within minutes: nausea, elevated heart rate, headache, and in serious exposures, seizures. OSHA classifies nicotine as a hazardous substance, and EPA regulates it as an acute toxicity Category I compound.

Dry powder is significantly safer in a manufacturing environment. While inhalation precautions are still necessary, the risk of acute dermal absorption is dramatically lower with a crystalline solid than with a concentrated liquid. This reduces the cost and complexity of safety controls, simplifies storage (no secondary containment for liquid spills), and integrates directly into the dry-mix processes that pouch production lines already use.

For facilities that need to meet GMP and ISO requirements, the risk assessment for handling bitartrate dihydrate powder is substantially simpler than for liquid nicotine. That means faster facility qualifications and fewer regulatory hurdles during site inspections.

Fast Dissolution Where It Counts

The dihydrate form dissolves readily in water, and it is supplied as a water-soluble crystalline salt precisely because the oral formats depend on that property. When a pouch contacts saliva, the bitartrate releases nicotine efficiently for absorption through the oral mucosa. Good solubility means the user gets a consistent experience from the first minute to the last. If your process needs a solubility figure at a stated temperature, request it against the current controlled specification rather than working from a typical value you found published somewhere.

The dissolution rate is also relevant. Because the dihydrate form already contains water of crystallization, it does not need to hydrate before dissolving. This gives it a faster dissolution onset compared to anhydrous nicotine salts, which can be a meaningful differentiator in consumer experience testing.

Applications Beyond Pouches

Lozenges

The defined nicotine content and water solubility make bitartrate dihydrate a natural fit for lozenges where controlled dissolution and consistent dosing are non-negotiable. Lozenge formulations typically target 1mg, 2mg, or 4mg nicotine per unit. With bitartrate dihydrate, the calculation is straightforward and the weight tolerance on each lozenge directly translates to a predictable nicotine dose. Nicotine polacrilex remains the standard for gum-based NRT, but for lozenges, bitartrate dihydrate is gaining share because of its simpler formulation requirements.

Nicotine Gums

The crystalline form distributes uniformly within a gum matrix. Pharmaceutical-grade material meets the stringent purity requirements for NRT products. While polacrilex resin-based systems dominate the commercial gum market (and are specifically described in pharmacopoeia monographs), some newer formulations are exploring bitartrate dihydrate as an alternative active ingredient, particularly for products targeting markets outside the traditional NRT channel.

Sublingual Tablets

An emerging NRT format that benefits from the compound's rapid dissolution and predictable release profile. Sublingual delivery bypasses first-pass metabolism, improving bioavailability. The fast dissolution of bitartrate dihydrate in a small volume of saliva makes it well-suited for this application, and several clinical-stage NRT programs are using it as the nicotine source.

Research and Analytical Standards

Bitartrate dihydrate is also widely used as a reference standard in analytical chemistry. Its defined stoichiometry and high purity make it suitable for preparing nicotine calibration standards, which are essential for HPLC and GC methods used in quality control across the industry.

The global pouch market is the primary growth driver, but the same properties that make bitartrate dihydrate ideal for pouches apply across oral nicotine products. As nicotine salt formulations continue to diversify, the bitartrate form is increasingly the starting point for product development.

Quality Specifications

Two different things get called a specification, and a procurement conversation goes badly when they are confused. The first is what the product specification and the lot certificate actually commit to. For the nicotine bitartrate dihydrate we supply, that is:

• Description: White or almost white powder
• Identification: Infrared absorption against the nicotine bitartrate dihydrate reference standard
• Nicotine content: 30.0-35.0%, with the sample batch reporting 32.57%
• pH: 3.0-3.4
• Specific optical rotation: +21.0 to +23.0, confirming the L-nicotine enantiomer
• Purity and impurities: Confirmed against the current controlled specification, with the assayed values on the batch-specific certificate

The second is everything your particular application needs that a general product specification does not fix: particle size distribution, microbial limits, elemental impurities, residual solvents. Those belong in your own incoming material specification, agreed with the supplier in writing and confirmed against the controlled records for the grade you are buying. Do not carry a number for any of them across from a datasheet you found online, and do not let a supplier infer one for you.

For EU manufacturers operating under the TPD or US manufacturers subject to FDA oversight, every shipment needs batch-specific COAs and full chain-of-custody documentation. An STC-certified supplier is not a nice-to-have. It is a procurement requirement. The difference between a supplier who provides template COAs and one who provides batch-specific analytical data is the difference between a smooth regulatory filing and a deficiency letter.

Storage and Handling Best Practices

Nicotine bitartrate dihydrate is hygroscopic. Improper storage can cause caking, clumping, and degradation. Keep these guidelines in mind:

• Store at 15-25°C in a dry environment (below 60% RH)
• Keep containers sealed when not in active use
• Use nitrogen blanketing for long-term storage of bulk quantities
• Rotate stock on a first-in, first-out basis
• Protect from direct light, even though the crystalline form is more light-stable than liquid nicotine

What to Ask Your Supplier

Are they providing batch-specific COAs with full analytical data? Can they show complete chain of custody from tobacco source to finished product? Are they manufacturing under ISO 9001, HACCP, and GMP conditions? Can they scale with you as your production ramps? Do they have USP/EP grade nicotine as the starting material for their salt synthesis?

If any answer is no, you are taking on risk that will surface at the worst possible time: during a regulatory audit or a customer complaint investigation.

NicAlliance supplies pharmaceutical-grade nicotine bitartrate dihydrate with STC traceability, batch-specific COAs, and the technical support to help you get your formulation right the first time. Request a quote and our team will respond within 24 hours.

Frequently Asked Questions